29 May 2026 by admin in UncategorizedComments Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds
28 May 2026 by admin in UncategorizedComments Avenzo Therapeutics Announces First Patient Dosed in Combination Cohort Evaluating CDK4 Selective Inhibitor (AVZO-023) with CDK2 Selective Inhibitor (AVZO-021) In Ongoing Phase 1/2 ORION-1 Study
28 May 2026 by admin in UncategorizedComments Zenas BioPharma Anounces Submision of Biologics License Aplication (BLA) to U.S. FDA for Obexelimab in IgG4-RD FDA for Obexelimab in IgG4-RD
18 May 2026 by admin in UncategorizedComments Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia
06 May 2026 by admin in UncategorizedComments Alebund Pharmaceuticals Announces Completion of Patient Enrollment in Global Phase III Pivotal Multi-Regional Clinical Trial of AP301 for Hyperphosphatemia
05 May 2026 by admin in UncategorizedComments Sail Biomedicines Appoints Gene Marcantonio, M.D., Ph.D., as Chief Medical Officer
04 May 2026 by admin in UncategorizedComments Windward Bio Announces $165M Crossover Financing to Advance Pipeline of Long- Acting Immunology Therapies With Best-in-Disease Potential
04 May 2026 by admin in UncategorizedComments NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
